Andrew Yee, MD
@andrew02114
Followers
1K
Following
3K
Media
50
Statuses
896
Medical oncologist at @MGHCancerCenter, Asst. Prof. of Medicine @harvardmed, focusing on patient care and trials in multiple myeloma and plasma cell disorders.
Boston, MA
Joined May 2009
Super useful table by @bdermanmd for benchmarking depth of response with induction therapy, especially as trials in newly diagnosed MM are starting to include anti-BCMA therapies which may take things further.
7500 – MIDAS Trial: MRD-Guided Therapy Post-IsaKRd. 718 NDMM pts. After Isa-KRd x6, 67% were MRD− at 10⁻⁵. Randomized to continue Isa-KRd x 6 or go to ASCT prior to maintenance. No difference in MRD<10⁻6 (84% vs 86%) thus far! .And as for MRD(+) post-induction: no difference
0
1
12
Subcutaneous isatuximab is on the horizon! Press release on phase 3 IRAKLIA study shows s.c. similar to i.v. (as would be expected). Hopefully this will enable approval and availability of s.c. isatuximab soon!
sanofi.com
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary...
2
10
44
This was a very practical poster at #ASH24, looking at prolonged dosing intervals of teclistamab, which is very relevant as dosing of tec (and other bispecific antibodies) moves to q4 week (or even longer intervals). New recommendation: if dosing interval ≤62 days, no need to
0
13
40
Joining in for #ASHaiku #ASH24. In San Diego,.friends gather, sharing new hope.for myeloma. (with some assistance from ChatGPT 😀).
☀️ Awaken your inner poet and write your best haiku about #ASH24 or #hematology! That's 3 lines in a 5-7-5 syllable pattern. Post now through Tuesday afternoon and include #ASHaiku. You might get included in a highlights post!. 🛑Remember, there's only one H in #ASHaiku!
1
3
18
The sensitivity of the more sensitive mass spec platforms for detecting disease may rival NGS and has the potential to replace bone marrow assessments!. Ongoing questions are to how to take into account when monoclonal protein is still present due to the half life of the.
1
4
16
The table is from a commentary that accompanies @bdermanmd excellent study looking at the performance of EXENT in the ATLAS study and how it can complement bone marrow-based MRD assessments.
ashpublications.org
Key PointsMS provides significant prognostic information in the maintenance setting and complements BM MRD in multiple myeloma.Without the aid of a baselin
1
4
9
Mass spectrometry is one of the most sensitive ways for detecting monoclonal protein in the peripheral blood. Similar to how there are different ways of detecting MRD in bone marrow (next generation sequencing or flow cytometry), there are different types of mass spec platforms
3
23
66
RT @Transplant_Doc: An ATLAS to map MRD with peripheral blood: a nice editorial on mass spec in MM #mmsm #bmtsm @andrew02114 .
ashpublications.org
In this issue of Blood, Kubicki et al1 report on findings from the EXENT platform (Thermo Fisher)—a new assay that uses mass spectrometry (MS) to measure s
0
8
0
RT @BloodCancerJnl: Improving outcomes with anti-BCMA bispecific antibodies with attention to infection | Blood Cancer Journal. @andrew0211….
nature.com
Blood Cancer Journal - Improving outcomes with anti-BCMA bispecific antibodies with attention to infection
0
4
0
Thanks @RahulBanerjeeMD! We're looking forward to presenting the poster at ASCO. Excellent outcomes when using daratumumab combinations upfront for patients hospitalized with acute kidney injury (including on dialysis) from myeloma. And this is without plasmapheresis.
10/ #ASCO24 #MMsm abstracts:. Abstract #7525 (Kim et al): Renal recovery with inpatient dara for acute cast nephropathy. Median time to ≥50% LC reduction with 🏥 dara (e.g. D-CyBorD) only 3 days. Inpatient dara cheaper & easier than PLEX, right??.
2
2
16
This case highlights the importance of taking into account medications like aflibercept (which is being used more frequently by ophthalmology) when evaluating patients with suspected POEMS syndrome and interpreting VEGF.
0
1
3
With time off from aflibercept, the VEGF level rose significantly, then dropped with treatment of POEMS with daratumumab, lenalidomide, dexamethasone, and the patient felt significantly better too.
1
1
5
It turns out that the patient was on aflibercept for macular edema, and I wasn't aware until this case that an injection in the eye of aflibercept of only 2 mg can dramatically lower systemic VEGF levels!
1
0
1
The ODAC on 3/15/24 on cilta-cel and ide-cel was like a plenary or late breaking abstracts session at ASH along with elements of America’s Got Talent. Lots of data being presented, discussion and analysis, and voting too!.
2
2
27
Cilta-cel data after prior BCMA therapy presented by @CohenAd_MMdoc #ASH22 and published
pubmed.ncbi.nlm.nih.gov
B-cell maturation antigen (BCMA)-targeting therapies, including bispecific antibodies (BsAbs) and antibody-drug conjugates (ADCs), are promising treatments for multiple myeloma (MM), but disease may...
0
0
4
Compare this with lower response rates with cilta-cel and PFS 5.3 m after anti-BCMA bispecific antibody. Interpretation limited by very small numbers of pts in both cases but raises the question of choice of bispecific antibody before anti BCMA CAR T (if used).
1
0
4
Some emerging data on efficacy of anti-BCMA CAR T-cell after talquetamab presented by Larysa Sanchez at #ash23 showing respectable response rates (though very interested in PFS):
1
6
34
